Cutaneous and ocular toxicologyHumansPsoriasisMaleFemaleMiddle Aged
Effect of interleukin 23 inhibitors (risankizumab and guselkumab) on cardiovascular and cerebrovascular risk in psoriasis patients.
Sibel Yıldız, Selami Aykut Temiz, Recep Dursun, Munise Daye, İlkay Özer, Melike Kıran
Published: 202510.1080/15569527.2025.2570206
Abstract
BACKGROUND: Psoriasis is a chronic systemic inflammatory disease mediated by the immune system. Interleukin-23 (IL-23) plays a key role in its pathogenesis by amplifying inflammation, triggering atherogenic dyslipidemia and insulin resistance, and th…
Preview only. Read the full abstract at the source